• Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib.

      Cushen, Samantha J; Power, Derek G; Teo, Min Y; Maceneaney, Peter; Maher, Michael M; McDermott, Ray; O'Sullivan, Kathleen; Ryan, Aoife M; *Department of Food & Nutritional Sciences ∥School of Mathematical Science, University College Cork †Department of Medical Oncology, Mercy & Cork University Hospitals §Department of Radiology, Mercy University Hospital, Cork ‡Department Medical Oncology, Adelaide & Meath Hospital incorporating National Children's Hospital, Tallaght, Ireland. (2014-04-21)
      Sunitinib is a standard first-line option for metastatic renal cell carcinoma (mRCC). Body composition is a prognostic factor in cancer patients and patients with loss of skeletal muscle mass and fat-free mass (FFM) are prone to dose-limiting toxicity (DLT) during targeted drug therapy. We investigated whether body composition by computed tomography predicted DLT from sunitinib in mRCC.